Research coauthored by RTI Health Solutions researchers will be presented at the 2023 Respiratory Synctial Virus Foundation.
Projected impact of RSV vaccine in US adults ≥ 60 years of age. Talbird SE, Cook C, DeMartino JK, Hernandez Pastor L, Krishnarajah G. Poster
Modeling the clinical and economic burden of respiratory syncytial virus (RSV) among adults ≥60 years of age in the United States. Molnar D, La E, Verelst F, Curran D, Poston S, Graham J. Poster
Respiratory syncytial virus versus influenza hospitalizations among adults ≥60 years in the United States. Parikh R, DeMartino JK, Krishnarajah G, Hitchens A, Bello F, Meyers J, Levin M. Poster
Respiratory syncytial virus–attributable hospitalizations among adults ≥60 years in the United States – a comparison by race/ethnicity. Parikh R, DeMartino JK, Krishnarajah G, Hitchens A, Bello F, Meyers J, Levin M. Poster
